Straits Times Index
3,212.64 -6.36 (-0.20%) Nikkei
27,385.25 -34.36 (-0.13%) Hang Seng
19,915.68 -133.96 (-0.67%) FTSE 100
7,405.45 -94.15 (-1.26%) Bitcoin USD
27,513.30 -587.27 (-2.09%) CMC Crypto 200
597.33 -21.06 (-3.41%)
ABBV Jan 2025 140.000 call
| Previous close | 26.86 |
| Open | 29.40 |
| Bid | 28.95 |
| Ask | 30.50 |
| Strike | 140.00 |
| Expiry date | 2025-01-17 |
| Day's range | 29.40 - 29.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 138 |
- Motley Fool
Better Buy: AbbVie vs. Johnson & Johnson
AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) did something many other stocks didn't last year. After all, these stocks offer a track record of earnings growth and dividend increases. The company's mega-blockbuster immunology drug, Humira, recently started facing competition in the U.S. And AbbVie predicts that this will result in a 37% decline in the drug's sales this year.
- Zacks
Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL
Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951
- Motley Fool
2 High-Yield Dividend Stocks You Won't Regret Buying Right Now
High-yield dividend stocks can be great for managing the ongoing reset in global equity markets. Which high-yield dividend stocks are worth buying right now? Read on to find out more about these above-average passive income opportunities.
